Your browser is no longer supported. Please, upgrade your browser.
Settings
PULM Pulmatrix, Inc. daily Stock Chart
PULM [NASD]
Pulmatrix, Inc.
Index- P/E- EPS (ttm)-5.63 Insider Own6.20% Shs Outstand10.29M Perf Week-1.85%
Market Cap10.91M Forward P/E- EPS next Y-1.73 Insider Trans0.00% Shs Float9.14M Perf Month-21.48%
Income-20.60M PEG- EPS next Q-0.59 Inst Own16.50% Short Float7.32% Perf Quarter-53.49%
Sales0.20M P/S54.54 EPS this Y46.50% Inst Trans52.57% Short Ratio0.31 Perf Half Y-69.84%
Book/sh2.37 P/B0.45 EPS next Y-5.50% ROA-125.90% Target Price3.00 Perf Year-76.62%
Cash/sh0.25 P/C4.20 EPS next 5Y- ROE-168.50% 52W Range0.72 - 6.88 Perf YTD-55.85%
Dividend- P/FCF- EPS past 5Y23.10% ROI- 52W High-84.81% Beta1.68
Dividend %- Quick Ratio1.10 Sales past 5Y- Gross Margin- 52W Low45.14% ATR0.19
Employees6 Current Ratio1.10 Sales Q/Q- Oper. Margin- RSI (14)44.06 Volatility6.19% 15.52%
OptionableYes Debt/Eq0.00 EPS Q/Q59.10% Profit Margin- Rel Volume0.15 Prev Close1.06
ShortableNo LT Debt/Eq0.00 EarningsMay 10 BMO Payout- Avg Volume2.13M Price1.04
Recom- SMA20-18.26% SMA50-16.02% SMA200-65.64% Volume242,419 Change-1.42%
Feb-09-18Initiated H.C. Wainwright Buy $5
Apr-15-19 09:00AM  Pulmatrix and Cipla Technologies LLC enter into Definitive Agreement for the Development and Commercialization of Pulmazole PR Newswire
Apr-08-19 04:29PM  Pulmatrix, Inc. Announces Closing of $16.6 Million Upsized Public Offering PR Newswire
Apr-03-19 09:30PM  Pulmatrix, Inc. Announces Pricing of $14.4 Million Upsized Public Offering PR Newswire -22.77%
Apr-01-19 05:33PM  Pulmatrix News: PULM Stock Skyrockets on Asthma Drug Deal InvestorPlace +81.89%
02:34PM  Pulmatrix's stock rockets after deal with Cipla Technologies to develop, commercialize asthma treatment MarketWatch
09:00AM  Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole PR Newswire
Mar-14-19 09:45AM  Pulmatrix to Participate in Upcoming Investor Conferences PR Newswire +19.01%
Mar-12-19 12:22PM  Pulmatrix Regains NASDAQ Compliance PR Newswire
Mar-08-19 01:00PM  These Four Tech Stocks Could Set The Pace On Friday ACCESSWIRE +39.37%
Feb-19-19 09:00AM  Pulmatrix Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline PR Newswire -6.84%
Feb-12-19 09:30AM  Pulmatrix Receives Five Patents Supporting Claims for their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs PR Newswire -6.93%
Feb-08-19 07:00AM  Pulmatrix, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market PR Newswire -32.84%
Feb-07-19 09:00AM  Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study PR Newswire -9.46%
Feb-06-19 12:15PM  4 Biotech Stocks Making Moves on Wednesday (2/6/19) ACCESSWIRE
09:00AM  Pulmatrix, Inc. Announces Termination of Planned Offering Pursuant to Registration Statement on Form S-1 PR Newswire
Feb-05-19 12:45PM  Pulmatrix, Inc. Announces 1-for-10 Reverse Stock Split PR Newswire -9.37%
11:14AM  Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock PR Newswire
Jan-31-19 01:24PM  Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock PR Newswire -28.29%
Jan-30-19 09:52PM  Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock PR Newswire
04:01PM  Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock PR Newswire
Jan-28-19 11:27PM  Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock PR Newswire -9.62%
04:18PM  Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock PR Newswire
Nov-29-18 05:00AM  Pulmatrix Announces $3.0 Million Registered Direct Offering PR Newswire
Nov-21-18 09:30AM  Pulmatrix Announces Positive Final Results from the Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE Formulation of Itraconazole PR Newswire -5.73%
Nov-15-18 09:30AM  Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology PR Newswire -7.02%
Nov-14-18 04:30PM  Pulmatrix Reports Q3 2018 Results PR Newswire
Sep-18-18 11:45AM  Who Owns Most Of Pulmatrix Inc (NASDAQ:PULM)? Simply Wall St. +8.13%
Sep-17-18 09:35AM  Pulmatrix to present pre-clinical data on PUR1800 (RV1162) at the European Respiratory Society International Congress PR Newswire +5.36%
Aug-28-18 10:00AM  Pulmatrix to Present at the 20th Annual Rodman & Renshaw Global Investment Conference on September 5, 2018 PR Newswire +5.99%
Aug-03-18 09:00AM  Pulmatrix Reports Q2 2018 Results PR Newswire -11.49%
Jul-23-18 10:13AM  Pulmatrix Announces the Formation of the Pulmazole Clinical Advisory Board to Support Future Development PR Newswire
Jul-20-18 07:20AM  Free Technical Research on Riot Blockchain and Three More Biotech Equities ACCESSWIRE
Jul-17-18 09:00AM  Pulmatrix Announces Positive Top-Line Preliminary Results from Part 3 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE Formulation of Itraconazole PR Newswire
Jun-25-18 08:30AM  Pulmatrix Announces Positive Top-Line Results from Parts 1 and 2 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE Formulation of Itraconazole PR Newswire
Jun-13-18 09:35AM  Pulmatrix Announces Publication of Results from a Phase 1 Pharmacodynamic Study of PUR0200 in COPD Patients PR Newswire +6.48%
Jun-07-18 09:30AM  Pulmatrix Announces Approval of Proposals Submitted to Company's Stockholders PR Newswire +9.73%
Jun-04-18 07:40AM  Wired News - Madrigal Pharma Reported Encouraging Top-line Data at 36 Weeks from Phase-2 Clinical Trial of MGL-3196 in Patients with NASH ACCESSWIRE
07:20AM  Initiating Free Research Reports on Pulmatrix and Three Other Biotech Equities ACCESSWIRE
May-25-18 12:49PM  Interested In Pulmatrix Inc (NASDAQ:PULM)? Heres How It Performed Recently Simply Wall St.
May-17-18 09:35AM  Pulmatrix selected to present company profile at the 2018 Respiratory Innovation Summit in San Diego PR Newswire
May-11-18 09:00AM  Pulmatrix Reports Q1 2018 Results PR Newswire
Mar-29-18 12:02AM  Pulmatrix Announces Pricing Of $15.2 Million Underwritten Public Offering PR Newswire -30.28%
Mar-13-18 04:42PM  Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary Disease Pipeline PR Newswire
Mar-09-18 09:46AM  Is Pulmatrix Inc (NASDAQ:PULM) A Financially Sound Company? Simply Wall St.
Feb-12-18 09:35AM  Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE Formulation of Itraconazole PR Newswire
Jan-29-18 08:00AM  Todays Research Reports on Trending Tickers: Atossa Genetics and Pulmatrix ACCESSWIRE
Jan-28-18 11:01PM  Is Pulmatrix Inc (NASDAQ:PULM) Undervalued? Simply Wall St.
Jan-25-18 10:30AM  PULM: MHRA Authorizes CTA; Patient Screening Commences! Zacks Small Cap Research +15.07%
Jan-24-18 12:00PM  Pulmatrix Will Present Pulmazole Preclinical Data at the 8th Advances Against Aspergillosis Conference to be Held February 1 - 3, 2018 PR Newswire
Jan-22-18 10:25AM  Pulmatrix Announces Acceptance of a Clinical Trial Application in Europe for Pulmazole - an Inhaled Dry-Powder iSPERSE Formulation of Itraconazole PR Newswire
Dec-19-17 11:45AM  How Pulmatrix Incs (NASDAQ:PULM) EPS Dropped 13.7%, Did Its Industry Show Weakness Too? Simply Wall St.
Dec-04-17 05:10PM  Pulmatrix Inc (PULM): Time For A Financial Health Check Simply Wall St.
Nov-29-17 08:47AM  Pulmatrix, Inc. :PULM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
Nov-14-17 01:00PM  PULM: Business And Financial Update For Third Quarter 2017 Zacks Small Cap Research
Nov-09-17 04:30PM  Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials PR Newswire
Oct-31-17 11:00AM  Pulmatrix Presents at the North American Cystic Fibrosis Conference PR Newswire
Oct-30-17 09:45AM  Pulmatrix Appoints Dr. James Roach as Chief Medical Officer PR Newswire
Oct-24-17 10:00AM  Pulmatrix: Company to Watch in Lung Disease Market ACCESSWIRE
Oct-11-17 02:14PM  Is It Time To Buy Pulmatrix Inc (PULM)? Simply Wall St.
Oct-03-17 09:45AM  Pulmatrix Antifungal Drug Candidate Receives a Second "Qualified Infectious Disease Product" (QIDP) Designation from the FDA PR Newswire
Sep-27-17 08:10AM  Today's Research Reports on Trending Tickers: Opko Health and Pulmatrix ACCESSWIRE
Sep-21-17 09:50AM  Pulmatrix to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017 PR Newswire
Sep-20-17 09:40AM  Pulmatrix Receives Key Patents on its Inhaled Drug Delivery Technology and its COPD Drug PR Newswire
Sep-19-17 05:57PM  Is It The Right Time To Buy Pulmatrix Inc (PULM)? Simply Wall St.
02:04PM  CEO Robert Clarke Discusses Positive Developments from Partnerships Obtained within the Past Few Months GlobeNewswire
11:00AM  PULM: Influx Of Grant And Partnership Deal- Signs Of Growing Confidence In Pulmatrix Zacks Small Cap Research
Sep-08-17 09:30AM  Pulmatrix to Present at the Rodman & Renshaw Global Investment Conference on September 11, 2017 PR Newswire +5.17%
Sep-06-17 08:32AM  Pulmatrix Licenses Inhaled COPD Drug PUR0200 to Vectura Group plc PR Newswire -14.98%
08:00AM  Today's Research Reports on Trending Tickers: Pulmatrix Inc. and Portola Pharmaceuticals Inc. ACCESSWIRE
04:37AM  Vectura Announces Major New Tiotropium Bromide PI Development Programme Accelerated Through Licensing of Pulmatrix Technology Benzinga
Sep-05-17 10:00AM  Pulmatrix Receives Award from Cystic Fibrosis Foundation Therapeutics to Support Development of PUR1900 for the Treatment of Pulmonary Fungal Infections PR Newswire +39.55%
Aug-04-17 08:55AM  Pulmatrix Provides 2017 Company Year-to-Date Highlights and Q2 2017 Updated Financials PR Newswire
Aug-03-17 10:30AM  PULM: Pulmatrix Broadens Its Pulmonary Portfolio With Addition of In-Licensed Janssen Compound for COPD Zacks Small Cap Research
Jul-31-17 10:00AM  Pulmatrix Strengthens Its Financials and Improves Outlook ACCESSWIRE
Jun-26-17 10:00AM  Innovative Pulmatrix Drug Offers New Hope for Fighting Fungal Lung Infections Accesswire -5.30%
Jun-15-17 12:13PM  Amit D. Munshi Joins Pulmatrix's Board of Directors PR Newswire
Jun-13-17 09:00AM  Pulmatrix Licenses Novel Drug Candidates from RespiVert Ltd., a wholly owned subsidiary of Janssen Biotech, Inc. PR Newswire -5.16%
Jun-09-17 06:15AM  Zacks Initiates on Pulmatrix (NASDAQ:PULM) Zacks Small Cap Research
May-18-17 08:00AM  Today's Research Reports on Biotech Stocks to Watch: Pulmatrix and Puma Biotechnology Accesswire
May-17-17 10:00AM  Pulmatrix's Unique Inhaled Drug Candidate Has "Blockbuster" Potential, Says CFO Bill Duke Accesswire +18.88%
May-09-17 09:40AM  Pulmatrix Receives Key US Patent for its Inhaled Drug for COPD PR Newswire -5.34%
May-05-17 08:55AM  Pulmatrix Reports Q1 2017 Financial Results PR Newswire
May-03-17 09:50AM  Pulmatrix Appoints Ted Raad, MBA, as Chief Business Officer PR Newswire
Apr-11-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: TherapeuticsMD and Pulmatrix Accesswire
Apr-05-17 09:27AM  Q1 Roundup: Winners and Losers of Biotech Sector Investopedia
09:27AM  Q1 Roundup: Winners and Losers of Biotech Sector
Mar-31-17 12:00PM  Penny Stocks to Watch for April 2017 (ATRS, WRN) at Investopedia
Mar-27-17 09:45AM  Pulmatrix Adds Two Top Fungal Infection Experts to its Scientific Advisory Board PR Newswire
Mar-22-17 09:30AM  Today's Research Reports on Stocks to Watch: Pulmatrix and Aevi Genomic Medicine Accesswire
Mar-21-17 12:42PM  Pulmatrix Inhaled Drug Delivery Tech Gets EU Patent Investopedia
12:42PM  Pulmatrix Inhaled Drug Delivery Tech Gets EU Patent at Investopedia
12:40PM  Why Pulmatrix Investors Are Breathing a Sigh of Relief 24/7 Wall St.
12:40PM  Why Pulmatrix Investors Are Breathing a Sigh of Relief
09:40AM  Pulmatrix Receives European Patent for its Inhaled Drug Delivery Technology PR Newswire
Mar-17-17 05:09PM  PULMATRIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Mar-16-17 11:04AM  Pulmatrix, Inc. :PULM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017 Capital Cube
11:04AM  Pulmatrix, Inc. :PULM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017
Mar-15-17 02:09PM  Pulmatrix, Inc. :PULM-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
01:04PM  PULMATRIX, INC. Financials
Mar-10-17 09:07AM  PULMATRIX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. Pulmatrix, Inc. has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; and definitive agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.